ArticleMolecules (Basel, Switzerland)2023
Monitoring Pharmaceuticals and Personal Care Products in Drinking Water Samples by the LC-MS/MS Method to Estimate Their Potential Health Risk.
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incorporating a Screening-Level Risk Quotient (RQ_screen) for Assessing Human Health Risk of Pharmaceutical Residues in Consumption Water.International journal of environmental research and public health · 2026Pooled it
- Recent Advances in Liquid Chromatography-Mass Spectrometry (LC-MS) Applications in Biological and Applied Sciences.Analytical science advances · 2025Review
- Degradation of piroxicam and celecoxib from aqueous solution by high-energy electron beam as a Sustainable method.Heliyon · 2024Article
- Monitoring Pharmaceuticals and Personal Care Products in Healthcare Effluent Wastewater Samples and the Effectiveness of Drug Removal in Wastewater Treatment Plants Using the UHPLC-MS/MS Method.Molecules (Basel, Switzerland) · 2024Article
- Integrating environmental effects in the benefit-risk assessment of therapeutic products: a proposal and example for sustainable health and healthcare.Frontiers in drug safety and regulation · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
(1) The occurrence and accumulation of pharmaceuticals and personal care products in the environment are recognized scientific concerns. Many of these compounds are disposed of in an unchanged or metabolized form through sewage systems and wastewater treatment plants (WWTP). WWTP processes do not completely eliminate all active substances or their metabolites. Therefore, they systematically leach into the water system and are increasingly contaminating ground, surface, and drinking water, representing a health risk largely ignored by legislative bodies. Especially during the COVID-19 pandemic, a significantly larger amount of medicines and protective products were consumed. It is therefore likely that contamination of water sources has increased, and in the case of groundwater with a delayed effect. As a result, it is necessary to develop an accurate, rapid, and easily available method applicable to routine screening analyses of potable water to monitor and estimate their potential health risk. (2) A multi-residue UHPLC-MS/MS analytical method designed for the identification of 52 pharmaceutical products was developed and used to monitor their presence in drinking water. (3) The optimized method achieved good validation parameters, with recovery of 70-120% of most analytes and repeatability achieving results within 20%. In real samples of drinking water, at least one analyte above the limit of determination was detected in each of the 15 tap water and groundwater samples analyzed. (4) These findings highlight the need for legislation to address pharmaceutical contamination in the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.